Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | TNF | P01375 | 1/20 | 0.47 |
| ▸ | MDM4 | O15151 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | MMP9 | P14780 | 1/20 | 0.44 |
| ▸ | MMP8 | P22894 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29908049 | 1.00 | CASP3 (0.49) | CASP3KMT2ATNFMDM4TP53 | |
| SCHEMBL1737738 | 1.00 | CASP3 (0.49) | CASP3KMT2ATNFMDM4TP53 | |
| SCHEMBL7713563 | 1.00 | CASP3 (0.49) | CASP3KMT2ATNFMDM4TP53 | |
| SCHEMBL31606673 | 1.00 | CASP3 (0.49) | CASP3KMT2ATNFMDM4TP53 | |
| SCHEMBL15521327 | 1.00 | CASP3 (0.49) | CASP3KMT2ATNFMDM4TP53 | |
| SCHEMBL22433817 | 1.00 | CASP3 (0.49) | CASP3KMT2ATNFMDM4TP53 | |
| SCHEMBL29400370 | 0.89 | CASP3 (0.51) | CASP3KMT2AMDM4TP53PIN1 | |
| SCHEMBL27128404 | 0.89 | CASP3 (0.51) | CASP3KMT2AMDM4TP53PIN1 | |
| SCHEMBL27028719 | 0.89 | CASP3 (0.51) | CASP3KMT2AMDM4TP53PIN1 | |
| SCHEMBL29447741 | 0.89 | CASP3 (0.46) | CASP3KMT2AMDM4TP53PIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6372883-B1 | FOR THERAPY AND PROPHYLAXIS OF INFECTIONS CAUSED BY HEPATITIS C, HEPATITIS G AND HUMAN GB VIRUSES | HOFFMANN-LA ROCHE INC. | 2002-04-16 | — | — | US | disclosed |